Living Off Dividends at 65: 3 Stocks That Raised Payouts for Longer Than 30 Years

For a 65-year-old investor who is planning to live on portfolio income rather than trade around it, an unbroken record of annual dividend increases matters more than a fat starting yield. A raise streak that stretches back decades tells you the check has survived recessions, wars, product recalls, and management changes without ever going backward. All three names below are verified Dividend Kings with streaks that far exceed 30 years, and one of them, Procter & Gamble, has now paid a dividend for 136 consecutive years, a track record most retirees will never outlive.

Johnson & Johnson (JNJ): 64 Years of Raises Backed by a AAA-Rated Balance Sheet

Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) is the healthcare anchor for an income-first retiree. Shares trade around $272.34 with a current dividend yield of 1.97%, backed by an annualized forward dividend of $5.36 per share. The streak is the real story: the Q1 2026 increase to $1.34 quarterly marked the 64th consecutive year of dividend increases.

Dividend safety is as durable as it gets in large-cap pharma. Diluted trailing EPS of $8.62 comfortably covers the annualized payout, and full-year 2025 free cash flow of $19.70 billion dwarfs the dividend outflow. Management guided full-year 2026 free cash flow approaching $21 billion, with roughly $21 billion in cash and marketable securities against about $49 billion in debt. CFO Joe Wolk reaffirmed the priority on the call: “We also remain committed to returning capital directly to shareholders, primarily through our dividend.” J&J is also one of only two U.S.-based companies with a prime AAA credit rating.

The bull case: Diversification without dilution of quality: 28 platforms each generating more than $1 billion in annual sales, raised full-year 2026 guidance to adjusted operational EPS of $11.50 to $11.65, and a stable of growth drivers like Darzalex above $4 billion in the quarter with growth close to 18% plus Tremfya growth of 71%. Shares have also delivered on total return, up 56.63% over the trailing year.

The caveat: Stelara biosimilar erosion is real, with sales down 55.7% in Q2 2026, and the planned Orthopaedics separation adds execution risk that retirees should watch even if it does not threaten the dividend.

Procter & Gamble (PG): 70 Years of Increases and $10 Billion in Planned Dividend Cash

Procter & Gamble (NYSE:PG) is the consumer staple built so the dividend check barely notices what the economy is doing. Shares trade near $147.27 with a yield of 2.96% on a dividend per share of $4.259. The streak is best-in-class: the Q4 FY2026 quarterly dividend of $1.0885 marked the 70th consecutive year of dividend increases and the 136th consecutive year of dividend payments.

Coverage is the reason a retiree can sleep at night. FY2026 delivered operating cash flow of $19.56 billion and free cash flow of $15.84 billion, with adjusted free cash flow productivity of 100% for the year and 133% in the fourth quarter. The company returned over $15 billion of value to shareholders, over $10 billion in dividends, and $5 billion in share repurchase. For FY2027, management laid out a plan to pay over $10 billion in dividends and repurchase approximately $5 billion in common stock. Return on equity runs at 30.3%, and the shares carry a beta of just 0.377.

The bull case: A portfolio of essentials (Tide, Pampers, Gillette, Charmin, Crest, Dawn, Pantene) that clears the shelves whether the S&P 500 is up or down. CEO Shailesh Jejurikar summed up the discipline: “We continued a long-term record of returning high levels of cash to shareholders.” Guidance for FY2027 core EPS is $6.89 to $7.11 per share, more than enough to fund the payout.

The caveat: FY2027 carries an approximately $1 billion after-tax cost headwind from higher raw materials, energy, transportation costs, and other premiums, and Q4 FY2026 organic sales were roughly flat, hinting at constrained pricing power near term. Both cap the pace of raises while leaving the dividend intact.

Coca-Cola (KO): A Global Cash Engine Behind Six Decades of Rising Payouts

Coca-Cola (NYSE:KO) closes the trio with the most global reach and the smoothest cash conversion. Shares recently changed hands at $87.43, and the yield sits at 2.42%, based on an annualized forward dividend of $2.12 per share. The current quarterly rate is 53 cents, up from 51 cents in 2025 and 48 cents in 2024. The company is a well-known Dividend King with a raise streak comfortably longer than 30 years.

Safety leads here too. Trailing EPS of $3.33 covers the annualized dividend, and margins are exceptional: operating margin of 34.9%, profit margin of 28.6% and return on equity of 42%. Free cash flow through the first half of 2026 came in at approximately $6.9 billion, with management guiding full-year free cash flow of about $12.4 billion. The balance sheet has room to spare: net debt leverage of 1.4 times EBITDA, which is below the target range of 2 to 2.5 times. CFO John Murphy told investors that “we have increased flexibility and optionality to continue to both reinvest in our business and return capital to share owners.”

The bull case: Unmatched brand equity and consumer reach. Q2 2026 delivered organic revenue growth of 6% and unit case volume growth of 5%, and Coca-Cola raised full-year comparable EPS growth guidance to 9 to 10% versus $3 in 2025. The FIFA World Cup 2026 marketing push generated more than 9 billion views through digital and social media activations. Shares are up 36.65% over the trailing year.

The caveat: Valuation. KO trades at a trailing P/E of 27 and a price-to-free-cash-flow multiple of roughly 72, so the payout absorbs a large slice of FCF. Retirees are paying a premium for the reliability.

How the Three Kings Stack Up for a Retiree

These three names give a 65-year-old investor exactly what the paycheck used to provide: a rising, defensible stream of quarterly cash from healthcare and consumer staples cash engines whose raise streaks span 64, 70, and multi-decade histories respectively. For retirees prioritizing yield and the longest streak, Procter & Gamble screens strongest on those measures. Its 2.96% yield sits above the other two, the 70-year raise streak is the longest in the group, and management has already committed to over $10 billion in dividends in FY2027. Johnson & Johnson screens well on balance-sheet strength via its AAA rating and healthcare diversification, while Coca-Cola offers the global staples exposure to complement the other two.

Contact [email protected] for any questions or corrections.